Safety and Effectiveness of Daptomycin Across a Hospitalized Obese Population: Results of a Multicenter Investigation in the Southeastern United States
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy2013Vol. 33(12), pp. 1322–1330
Citations Over TimeTop 17% of 2013 papers
P. Brandon Bookstaver, Christopher M. Bland, Zaina P. Qureshi, Carmen Faulkner-Fennell, Margrit A. Sheldon, Celeste R. Caulder, Charles Hartis, SERGE‐45 Investigators
Abstract
Although elevations in CPK increased in high-risk obese patients on daptomycin, discontinuation rates due to ADEs remained low. Further evaluation in a prospective trial is warranted.
Related Papers
- → Addition of Ceftaroline to Daptomycin after Emergence of Daptomycin-Nonsusceptible Staphylococcus aureus during Therapy Improves Antibacterial Activity(2012)111 cited
- → Establishing the Structure–Activity Relationship of Daptomycin(2020)40 cited
- → Mechanisms of daptomycin resistance in Staphylococcus aureus(2006)81 cited
- → The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA(2014)42 cited
- → Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach(2016)7 cited